Figure 1From: Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial (A) Study design and (B) population. Schedule of assessments: a = iFGF23, cFGF23, 25-hydroxyvitamin D, 1–25 dihydroxyvitamin D, bone-specific ALP, iPTH; b = eGFR; c = 24-h urinary phosphate, calcium creatinine and urea nitrogen; d = iGFR, ionized calcium, CrossLaps®; e = adverse events. ALP, alkaline phosphatase; cFGF23, C-terminal fibroblast growth factor 23; eGFR, estimated glomerular filtration rate; iFGF23, intact fibroblast growth factor 23; iGFR, iohexol glomerular filtration rate; iPTH, intact parathyroid hormone.Back to article page